The MAT2B Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from human Raji B lymphocytes, featuring disruption of the MAT2B gene. This product provides a heterogeneous loss-of-function model without single?cell clonal selection, enabling studies of MAT2B ablation in a lymphoma-relevant background.
Raji is an EBV-positive Burkitt’s lymphoma B-cell line widely used in immunology and oncology research. It retains key features such as antibody production, antigen presentation, and immune memory functions, offering a well-characterized platform for investigating B-cell malignancies and metabolic dysregulation.
MAT2B encodes the regulatory ?? subunit of methionine adenosyltransferase II, which partners with catalytic MAT2A to generate S-adenosylmethionine (SAM) from methionine and ATP. MAT2B senses methionine availability, modulating MAT2A activity, and also acts as a transcriptional corepressor, bridging one-carbon metabolism to epigenetic control. Upstream regulators MYC, SP1, NF-Y, and SREBP1 control MAT2B expression, while downstream effects encompass MAT2A levels, DNA and histone methylation, phosphatidylcholine synthesis, and polyamine production. Through interactions with BAF53a, actin, and corepressor complexes, MAT2B integrates metabolic signals with chromatin remodeling.
In Raji lymphoma cells, MAT2B knockout permits dissection of how methionine metabolism drives malignant phenotypes. Dysregulated SAM synthesis and aberrant methylation are common in cancer, and MAT2B is linked to hepatocellular carcinoma, colorectal cancer, and liver fibrosis. Disrupting MAT2B in this B-cell model allows investigation of altered SAM homeostasis, epigenetic reprogramming by DNA methyltransferases (DNMTs) and histone methyltransferases that depend on SAM, and transcriptional changes that sustain lymphoma growth, providing insights into metabolic vulnerabilities of EBV-driven B-cell malignancies.
Researchers can use these polyclonal knockout cells to measure SAM levels via LC-MS, assess global DNA methylation and histone modification profiles using Western blotting or sequencing-based methods, and evaluate proliferation and apoptosis. Transcriptomic analysis by RNA-seq and protein interaction studies by co-immunoprecipitation further elucidate MAT2B-dependent networks. Applications include drug target validation for MAT2A/MAT2B inhibitors and high-throughput screening of metabolic modulators in lymphoma. For additional information, contact Ascent Research.
